Introduction
This information will help you understand your choices, whether you share in the decision-making process or rely on your doctor's recommendation.
Key points in making your decision
Your decision about whether to treat multiple sclerosis (MS) with medications—called disease-modifying therapy—will depend largely on your doctor's recommendation and your own views about the benefits and drawbacks of treatment. Disease-modifying means treatment to delay, change, or interrupt the natural course or progression of a disease.
Consider the following when making your decision:
- The National Multiple Sclerosis Society and most neurologists recommend starting treatment with either interferon beta or glatiramer acetate as soon as MS is diagnosed. Mitoxantrone (Novantrone) is considered when other treatments fail to control symptoms or progression of the disease. Most experts now agree that permanent damage to the nervous system may occur early on, even while your symptoms are still quite mild. Early treatment may help prevent or delay this damage.
- MS is unpredictable. Doctors cannot know with certainty whether you will progress to a more severe form of the disease. A small number of people with MS have only mild disease and do well without treatment, but most get worse over time.
- Interferon beta or glatiramer acetate can reduce the frequency and severity of attacks of relapsing-remitting MS and may reduce or delay disability. However, doctors cannot predict whether the medications will work for you.
- Disease-modifying medications for MS may have significant side effects, including flu-like symptoms such as fever, chills, fatigue, and muscle aches. One medication can even damage your heart (mitoxantrone).
- These medications are expensive; your cost will depend on your insurance coverage. However, some foundations and other organizations pay for MS treatment for those who cannot afford it; financial costs alone should not keep you from considering treatment.
Medical Information
What is multiple sclerosis?
Multiple sclerosis (MS) is a disease of the central nervous system (CNS) that can cause problems with muscle control and strength, balance, vision, and sensation (such as numbness or tingling in your feet or hands).
The symptoms of MS are caused by inflammation of the CNS and the destruction of myelin, the coating that surrounds and protects nerve fibers (axons). The resulting damage disrupts the normal flow of nerve impulses through the brain, spinal cord, and nerves that control how a person moves and feels.
In general, MS follows one of four courses, which are called:
The severity of MS differs from person to person and can vary within one person over time. Some people have only mild problems with vision or sensation, while others have severe problems with movement, causing disability.
How is multiple sclerosis diagnosed?
Health professionals diagnose the disease when damage typical of MS has occurred to more than one area of the brain or spinal cord at more than one point in time. This means that you have had at least two episodes of signs and symptoms that could be caused by MS, such as weakness or clumsiness, vision problems, tingling or numbness, or balance problems that a neurologist can verify.
Each episode must have lasted at least 24 hours, and the episodes should have occurred at least 1 month apart. If you have MS, a magnetic resonance imaging (MRI) test usually shows damage (lesions or plaques) in more than one area of the brain or spinal cord.
How effective are medications for MS?
Medications cannot cure MS at this time. They do not stop disease activity or progression, and they do not reverse nervous system damage that has already occurred. However, medications may reduce relapses and delay disability in many people with relapsing forms of MS. Studies have shown that:
- For people with relapsing-remitting MS, interferon beta (Avonex, Rebif, or Betaseron) can reduce the severity of relapses, and decrease their frequency by about one-third. They may also delay disability in some people, and decrease the occurrence of new areas of damage (lesions).1 High doses of interferon beta given more frequently (such as 3 times per week) is more effective than lower doses given less often.2, 3
- Glatiramer acetate (Copaxone) can make relapses less severe. It can also decrease their frequency by about one-third, like the interferon beta drugs. But less is known about the effect on MS lesions or on the development of disability. Doctors often use glatiramer acetate in milder cases of MS.1
- Mitoxantrone (Novantrone) can also slow disease progression and decrease relapse rates in people with relapsing-remitting and secondary progressive MS, but with a greater chance of side effects.4
- Early treatment, beginning as soon as relapsing MS is diagnosed, seems to be most effective and is recommended by the National Multiple Sclerosis Society.5
If you need more information, see the topic Multiple Sclerosis.
Your Information
Your choices are:
- Take disease-modifying medications as soon as you are diagnosed with MS. Research shows that treatment at diagnosis may result in fewer and less severe relapses and may delay damage to the nervous system.
- Wait to see how the disease progresses.
The decision about whether to take medications for MS takes into account your personal feelings and the medical facts.
| Reasons to take disease-modifying medications | Reasons not to take disease-modifying medications |
|---|---|
Are there other reasons you might want to take medications for MS? |
Are there other reasons you might not want to take medications for MS? |
These personal stories may help you make your decision.
Wise Health Decision
Use this worksheet to help you make your decision. After completing it, you should have a better idea of how you feel about taking disease-modifying medication. Discuss the worksheet with your doctor.
Circle the answer that best applies to you.
| I want to follow the advice of experts, who say that early treatment might reduce relapses and delay disability. | Yes | No | Unsure |
| I am willing to take medication even though there is no way to predict whether it will work for me. | Yes | No | Unsure |
| I have only had one attack of symptoms and want to wait to see if I have any more relapses before taking medication. | Yes | No | Unsure |
| I am worried about the side effects of the medications. | Yes | No | Unsure |
| I am willing to accept side effects if the medications might help me. | Yes | No | Unsure |
| I am comfortable giving myself shots one to three times a week. | Yes | No | Unsure |
| My insurance will cover most or all of the cost of treatment. | Yes | No | Unsure |
Use the following space to list any other important concerns you have about this decision.
What is your overall impression?
Your answers in the above worksheet are meant to give you a general idea of where you stand on this decision. You may have one overriding reason to use or not use disease-modifying medications for MS.
Check the box below that represents your overall impression about your decision.
|
Leaning toward taking medication |
Leaning toward NOT taking medication |
Return to the topic Multiple Sclerosis.
References
Citations
Sadiq SA (2005). Multiple sclerosis. In LP Rowland, ed., Merritt's Neurology, 11th ed., pp. 941–963. Philadelphia: Lippincott Williams and Wilkins.
Durelli L, et al. (2002). Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet, 359(9316): 1453–1460.
Panitch H, et al. (2002). Randomized, comparative study of interferon beta-1a treatment regimens in MS: The evidence trial. Neurology, 59(10): 1496–1506.
Stuart WH, Vermersch P (2004). Concomitant therapy for multiple sclerosis. Neurology, 63(Suppl 5): S28–S34.
Medical Advisory Board of the National Multiple Sclerosis Society (2005). Disease Management Consensus Statement, Expert Opinion Paper, Treatment Recommendations for Physicians. New York, NY: National Multiple Sclerosis Society.
Credits
| Author | Shannon Erstad, MBA/MPH |
| Editor | Kathleen M. Ariss, MS |
| Associate Editor | Michele Cronen |
| Associate Editor | Pat Truman |
| Primary Medical Reviewer | Kathleen Romito, MD - Family Medicine |
| Specialist Medical Reviewer | Barrie J. Hurwitz, MD - Neurology |
| Last Updated | March 23, 2006 |
© 1995-2007, Healthwise, Incorporated, P.O. Box 1989, Boise, ID 83701. ALL RIGHTS RESERVED.
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information. For more information, click here. Privacy Policy. How this information was developed.